BRAF and melanoma: Furthermore, a study tracking stage-specific changes in macrophages during BRAF/MEK inhibitor treatment in a melanoma model revealed that the emergence of a drug-tolerant persistent state coincided with a peak in the infiltration of Ccr2+ monocytes, known for their negative regulation of angiogenesis and T cell activity [[70], [71], [72]].